Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Immunoprecise Antibodies Ltd
IPAImmunoPrecise Antibodies Ltd., a biotechnology company, leverages multi-omics modeling and artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; peptide production for subsequent antibody discovery campaign; B cell select platform, which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. In addition, it provides phage display, a custom immune library; CAR development, an adaptable antibody, which allows the inclusion of functional data early in the screening funnel; antibody sequencing; and assay development. Further, it offers a profiling toolset for antibody lead candidates; and in vitro analytical tools for the study of quality attributes. Additionally, it provides LucinaTech, an antibody humanization to identify framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; antibody chimerization for cloning and production of antibody domain; Eurofins preclinical services; hybrid service model designed to reduce time and risk with custom applications; breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts; and protein manufacturing services. The company is headquartered in Victoria, Canada. Address: 3204?4464 Markham Street, Victoria, BC, Canada, V8Z 7X8
Analytics
Preço Alvo de Wall Street
5.97 USDRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave IPA
Análise de Dividendos IPA
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos IPA
Avaliação de ações IPA
Relatório IPA
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |